Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie and Genmab are collaborating on a clinical study titled ‘Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)’. This Phase 1b/2 trial aims to evaluate the safety and preliminary efficacy of epcoritamab, alone or in combination with other treatments, for patients with B-NHL. The study is significant as it seeks to establish an effective treatment regimen for this type of lymphoma.
The trial investigates epcoritamab, a biological agent, in combination with various standard-of-care drugs. Epcoritamab is designed to target and treat B-cell non-Hodgkin lymphoma, potentially improving patient outcomes.
This interventional study is non-randomized with a parallel assignment model and no masking. Its primary purpose is treatment, focusing on safety and efficacy across multiple treatment arms.
The study began on November 3, 2020, with an active, not recruiting status as of the last update on August 4, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
The outcome of this study could significantly impact AbbVie and Genmab’s market positions, potentially boosting their stock performance if results are favorable. The study’s progress is closely watched by investors, given the competitive landscape in cancer treatment development.
The study is ongoing, and further details are available on the ClinicalTrials portal.